2Cil T, Altintas A, Pass S, et al. Lanfivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen ( HB- SAG) seropositive cancer patients undergoing cytotoxic chemother- apy[J]. Leuk lymphonla, 2008,49(5 ) :939-947.
3Dusheiko G, Song E, Bowyer S, et al. Natural history of hepatitis B virus infection in renal transplant recipients- a fifteen year follow- up [J]. Hepatology, 1983,3(3) :330-336.
4Degos F, Lugassy C, Degott C, et al, Hepatitis B virus and hepati- tis B-related viral infection in renal transplant recipients. A pro- spective study of 90 patients [ J ]. Gastroenterology, 1988,94 ( 1 ) : 151-156.
5Park SK, Yang WS, Lee YS, et al. Outcome of renal transplanta- tion in hepatitis B surface antigen-positive patients after introduc- tion of lamivudine [ J ]. Nephrol Dial Transplant, 2001,16 ( 11 ) : 2222 -2228.
6Marcellin P, Giostra E, Martinot-Peignoux M, et al. Redevelop- ment of hepatitis B surface antigen after renal transplantation [ J ]. Gastroenterology, 1991,100(5 Pt 1 ) : 1432-1434.
7Knoll A, Boehm S, Hahn J, et al. Reactivation of resolved hepati- tis B virus infection after allogeneic haematopoietic stem cell trans- plantation [ J ]. Bone Marrow Transplant, 2004,33 (9) :925-929.
8Onozawa M, Hashino S, humiyama K, et al. Progressive disap- pearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplanta- tion in patients with previous hepatitis B virus infection [ J]. Trans- plantation, 2005,79 ( 5 ) :616-619.
9Kusumoto S, Tanaka Y, Ueda R, et al. J Reactivation of hepatitis B virus following rituximab-plus-steroid [ J ]. Gastroenterol, 2011, 46( 1 ) :9-16.
10Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving ritux- imab[J]. N Engl J Med, 2001,344( 1 ) :68-69.
4Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
3Da|ia S,Suleiman Y, Croy DW,et al. Association of lymphomagene- sis and the reactivation of hepatitis B virus in non-hodgkin lympho- ma[J]. Cancer Cantrol,2015,22(3) :360 -365.
4Hsiao LT,Chiou TJ,Gau JP,et al. Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab-treated non-Hodgkin lymphoma patients:A Large Cohort Retrospective Study[ J]. Medi- cine ( Baltimore ) , 2015,94 ( 32 ) : e1 321.
5Li X,Fan XW ,Liu W ,et al. Risk factors for damaged liver function after chemotherapy in hepatitis B virus carriers with uon-Hodgkin lymphoma[ J]. Genet Mol Res,2015,14(1) :2647 - 2653.
6Steinke FC,Yu S,Zhou X,et al. TCF - 1 and LEF of Th - POK to promote the CD4( + ) T cell fate Runx3 to silence Cd4 in CD8(+) T cells[J] .act upstream and interact with Nat hnmunol, 2014,15(7) :646 -656.
7Kang EH,Lee YJ,Hyon JY,et al. Salivary cytokine profiles in pri- mary Sjogren' s syndrome differ from those in non-Sjogren sicca in terms of TNF - alpha levels and Th - 1/Th - 2 ratios [ J ]. Clin Exp Rheumatol,2011,29 (6) :970 - 976.
8Kerbrat S,Vingert B,Junier MP, et al. Absence of the adaptor pro- tein PEA - 15 is associated with altered pattern of Th cytokines pro duction by activated CD4 * T ]ymphneytes in vitro, and defective red blood cell alloimmune response in vivo[ J]. PLoS One,2015,10 (8) :e136885.
9Li B,Tian L,Diao Y,et aL Exogenous IL - 10 induces corneal trans- plantation immune tolerance by a mechanism associated with the al- tered Thl/Th2 eytokine ratio and the increased expression of TGF - beta[J]. Mol Med Rep,2014,9(6) :2245 -2250.
10Loria-Cervera EN, Sosa-Bibiano El, Villanueva-Lizama LE, et al. Cloning and sequence analysis of Peromyseus yueatanieus ( Roden- tia) Thl (IL-12p35, IFN-gammaand TNF) and Th2 (IL-4, IL - 10 and TGF - beta) eytokines [ J ]. Cytokine ,2014,65 (1) :48 -55.
